Welcome to our dedicated page for Cabaletta Bio SEC filings (Ticker: CABA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cabaletta Bio, Inc. filings document regulatory disclosures for a Nasdaq-listed biotechnology issuer developing engineered T cell therapies for autoimmune diseases. Form 8-K reports cover operating and financial results, corporate presentations, material agreements, and clinical or regulatory updates involving rese-cel and the RESET clinical development program.
Proxy materials describe annual meeting voting matters and governance for holders of Cabaletta Bio common stock. The filing record also identifies the company’s registered common stock, capital-structure disclosures, risk-oriented forward-looking statements, and formal material-event reporting tied to its cell-therapy development and manufacturing strategy.
Prudential Financial, Inc. amended its Schedule 13G to report beneficial ownership of 24,267,980 shares of Cabaletta Bio common stock, representing 11.4% of the class as reported. The filing shows shared voting power of 19,465,084 and shared dispositive power of 24,267,980, and identifies Jennison Associates LLC as the subsidiary holding these shares. The amendment is dated 05/31/2026 and was signed on 06/05/2026.
Jennison Associates LLC reports beneficial ownership of 24,267,980 shares (11.4%) of Cabaletta Bio Inc. The filing amends prior disclosures and shows Jennison holds 24,267,980 shares with sole voting power over those shares and shared dispositive power, filed with a reporting date of 05/29/2026 and signed 06/04/2026.
Cabaletta Bio reported new clinical data for its CD19 CAR-T therapy rese-cel across myositis, systemic sclerosis and lupus, alongside development plans toward pivotal trials. In Phase 1/2 RESET-Myositis, 80% of dermatomyositis and antisynthetase patients would have met the planned registrational primary endpoint, with most maintaining immunomodulator‑free responses for up to 1.5 years.
RESET-SSc patients with interstitial lung disease showed a median 7.5% improvement in lung function at 36 weeks and high rCRISS response rates while off immunomodulators. In RESET-SLE, 75% of preconditioned patients with 12‑month follow-up achieved remission by DORIS criteria off immunomodulators, with favorable safety: over 90% of patients across trials had no or only mild cytokine release syndrome and almost all had no ICANS. Cabaletta plans a ~25‑patient SSc registrational study starting 4Q26, topline myositis data in mid‑2027, and a 2H27 BLA including adult and juvenile dermatomyositis.
Cabaletta Bio, Inc. reports that Cormorant Asset Management and Bihua Chen hold 10,500,000 shares of Common Stock, representing 9.03% of the class. The holdings reflect Common Stock issuable upon exercise of warrants; the Warrants are exercisable for up to 5,000,000 shares. Shares outstanding were 111,322,671 as of March 19, 2026, per the company’s Form 10-K dated March 23, 2026.
The filing states the reported shares are held by the Cormorant Funds with shared voting and dispositive power of 10,500,000 and identifies Cormorant Global Healthcare Master Fund, LP as having economic rights to more than 5% of the shares.
Cabaletta Bio reports wider quarterly losses as it advances its rese-cel autoimmune cell therapy program and faces funding risk. For the three months ended March 31, 2026, the company recorded a net loss of $43.5 million on operating expenses of $44.3 million, driven mainly by $37.4 million in research and development spending. Cash and cash equivalents were $116.6 million at quarter-end, and a May 2026 equity offering raised an additional $141 million in net proceeds. Management notes an accumulated deficit of $560.5 million and explicitly states that substantial doubt exists about the company’s ability to continue as a going concern, even though current resources are expected to fund operations for at least 12 months.
Cabaletta Bio reports wider quarterly losses as it advances its rese-cel autoimmune cell therapy program and faces funding risk. For the three months ended March 31, 2026, the company recorded a net loss of $43.5 million on operating expenses of $44.3 million, driven mainly by $37.4 million in research and development spending. Cash and cash equivalents were $116.6 million at quarter-end, and a May 2026 equity offering raised an additional $141 million in net proceeds. Management notes an accumulated deficit of $560.5 million and explicitly states that substantial doubt exists about the company’s ability to continue as a going concern, even though current resources are expected to fund operations for at least 12 months.
Cabaletta Bio reported a larger first-quarter 2026 net loss of $43.5 million, or $0.39 per share, as it increased spending to advance its cell therapy pipeline. Research and development expenses rose to $37.4 million, while general and administrative costs were $6.9 million.
Cash, cash equivalents and short-term investments were $116.6 million as of March 31, 2026, down from $133.6 million at year-end 2025. The company also closed a $150 million registered direct offering in May 2026 and now expects to fund its operating plan into mid-2027.
Operationally, Cabaletta highlighted progress for its lead CAR T candidate rese-cel, including a pivotal RESET-Myositis cohort intended to support a planned Biologics License Application in 2027, expanding commercial manufacturing through a 10-year Cellares supply agreement, and multiple upcoming data readouts across its RESET trials in autoimmune diseases.
Cabaletta Bio reported a larger first-quarter 2026 net loss of $43.5 million, or $0.39 per share, as it increased spending to advance its cell therapy pipeline. Research and development expenses rose to $37.4 million, while general and administrative costs were $6.9 million.
Cash, cash equivalents and short-term investments were $116.6 million as of March 31, 2026, down from $133.6 million at year-end 2025. The company also closed a $150 million registered direct offering in May 2026 and now expects to fund its operating plan into mid-2027.
Operationally, Cabaletta highlighted progress for its lead CAR T candidate rese-cel, including a pivotal RESET-Myositis cohort intended to support a planned Biologics License Application in 2027, expanding commercial manufacturing through a 10-year Cellares supply agreement, and multiple upcoming data readouts across its RESET trials in autoimmune diseases.
Cabaletta Bio is highlighting new clinical and manufacturing data for its investigational CD19 CAR T therapy rese-cel in autoimmune diseases. In pemphigus vulgaris, four patients received the lowest preconditioning-free dose; all completed at least 24 weeks of follow-up.
All four showed early clinical improvement, and two maintained compelling, drug-free responses through six months. Three of four had complete peripheral B cell depletion, with antibody levels against DSG3 and DSG1 decreasing alongside disease activity scores.
The company also reports that the first two clinical rese-cel doses manufactured on Cellares’ fully automated Cell Shuttle met all release specifications, with key quality metrics and early pharmacology profiles consistent with prior manual manufacturing runs. Cabaletta plans to test higher PC-free doses and expand across lupus and other autoimmune indications during 2026.
Cabaletta Bio is highlighting new clinical and manufacturing data for its investigational CD19 CAR T therapy rese-cel in autoimmune diseases. In pemphigus vulgaris, four patients received the lowest preconditioning-free dose; all completed at least 24 weeks of follow-up.
All four showed early clinical improvement, and two maintained compelling, drug-free responses through six months. Three of four had complete peripheral B cell depletion, with antibody levels against DSG3 and DSG1 decreasing alongside disease activity scores.
The company also reports that the first two clinical rese-cel doses manufactured on Cellares’ fully automated Cell Shuttle met all release specifications, with key quality metrics and early pharmacology profiles consistent with prior manual manufacturing runs. Cabaletta plans to test higher PC-free doses and expand across lupus and other autoimmune indications during 2026.
Cabaletta Bio, Inc. is selling 51,725,000 shares of common stock at $2.90 per share in an underwritten public offering. Gross proceeds are expected to be about $150 million, with estimated net proceeds of approximately $141 million after underwriting discounts and expenses.
As of March 31, 2026, Cabaletta held about $117 million in cash and cash equivalents. The company plans to use the new capital with existing cash mainly to expand clinical development and manufacturing for its CD19 CAR-T candidate rese-cel, and now believes it can fund operations into mid‑2027.
Cabaletta Bio is conducting a primary offering of 51,725,000 shares of its common stock at $2.90 per share. The offering’s public offering price implies gross proceeds of $150,002,500 and expected net proceeds to the company of approximately $141,002,350.
Delivery is expected on or about May 5, 2026. Shares outstanding used for post-offering calculations were 100,479,323 as of December 31, 2025. The company states the net proceeds, together with existing cash and cash equivalents, are intended to fund expanded clinical development and manufacturing readiness and are expected to fund operations into mid-2027.
Cabaletta Bio filed a current report describing plans to present new clinical and translational data from four refractory pemphigus vulgaris patients treated with rese-cel in its RESET-PV trial. These patients received the lowest rese-cel dose without preconditioning chemotherapy and had 24–36 weeks of follow-up as of an April 2, 2026 data cut.
The company will share these data at the ASGCT 2026 Annual Meeting on May 14, 2026. Cabaletta also highlights broader development plans for rese-cel across several autoimmune diseases and notes it plans to add a new dose-escalation cohort to the RESET-SLE trial, with initial no-preconditioning dose data anticipated in the first half of 2026.